Literature DB >> 7929258

Myosin heavy chain synthesis is independently regulated in hypertrophy and atrophy of isolated adult cardiac myocytes.

W A Clark1, S J Rudnick, L C Andersen, J J LaPres.   

Abstract

Hypertrophy of isolated adult feline cardiac muscle cells may be induced in culture by either alpha- or beta-adrenergic agonists. However, it has been shown previously that each of these agonists activate different subsets of immediate-early response genes and have different effects on expression of "fetal" protein isoforms and stimulation of protein synthesis. Moreover, in adult feline heart cells, beta-adrenergic agonists, such as isoproterenol, activate sustained synchronous beating and sarcomeric reorganization while alpha-adrenergic agonists, such as phenylephrine, do not. The objective of the present study was to determine whether these differences in proximal signaling events converged in a common signal pathway during activation of contractile protein synthesis. By direct comparisons of actin and myosin heavy chain (HC) synthesis and accumulation following isoproterenol and phenylephrine, it was determined that both agonists stimulate a coordinated accumulation of these proteins during cardiomyocyte growth. However, each agonist stimulated a very different program of contractile protein synthesis. During phenylephrine-induced hypertrophy, actin and myosin HC syntheses were rapidly and coordinately activated and continuously maintained at rates 10-25% greater than untreated cultures. The pattern of myosin HC synthesis following isoproterenol was very much more complex with periods during which it was as much as 40% greater or 25% less than in control cultures. Furthermore, there was no correlation between rates of actin and myosin HC synthesis following isoproterenol. It was concluded that actin and myosin HC syntheses and accumulation were regulated independently and in a very different manner following isoproterenol or phenylephrine. Since protein accumulation was not correlated with synthesis rates during development of hypertrophy, it was also concluded that post-translational mechanisms played a significant role in the maintenance of contractile protein stoichiometry during beta-adrenergic/beating-induced hypertrophy. Myosin HC synthesis also appeared to be independently regulated during cardiomyocyte atrophy induced by the calcium channel blocker nifedipine. Unlike the case in hypertrophy, however, protein balance was not maintained in nifedipine, and the depression of myosin HC synthesis and loss of myosin HC content were much greater than in the case of other contractile proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929258

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

Review 1.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

2.  Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro.

Authors:  D Kaye; D Pimental; S Prasad; T Mäki; H J Berger; P L McNeil; T W Smith; R A Kelly
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 3.  Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.

Authors:  Brian C Jensen; Timothy D OʼConnell; Paul C Simpson
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

4.  The programming of cardiac hypertrophy in the offspring by maternal obesity is associated with hyperinsulinemia, AKT, ERK, and mTOR activation.

Authors:  Denise S Fernandez-Twinn; Heather L Blackmore; Lee Siggens; Dino A Giussani; Christine M Cross; Roger Foo; Susan E Ozanne
Journal:  Endocrinology       Date:  2012-10-15       Impact factor: 4.736

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.